As of Feb 27
| +0.22 / +0.46%|
The 30 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 48.66, with a high estimate of 58.72 and a low estimate of 39.31. The median estimate represents a +1.90% increase from the last price of 47.75.
The current consensus among 31 polled investment analysts is to Buy stock in Novo Nordisk. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.